Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
The DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.
Abstract
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently become a major concern for a broad spectrum of health care providers. Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM) are at center stage, as T2DM appears to worsen the course of NAFLD and the liver disease makes diabetes management more challenging. However, the nature of this relationship remains incompletely understood. Although the increasing prevalence of NAFLD is frequently attributed to the epidemic of obesity and is often oversimplified as the "hepatic manifestation of the metabolic syndrome," it is a much more complex disease process that may also be observed in nonobese individuals and in patients without clinical manifestations of the metabolic syndrome. It carries both metabolic and liver-specific complications that make its approach unique among medical conditions. Diabetes appears to promote the development of nonalcoholic steatohepatitis (NASH), the more severe form of the disease, and increases the risk of cirrhosis and hepatocellular carcinoma. Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and few pharmacological agents with proven efficacy. However, recent advances in diagnosis and treatment, combined with the risk of serious consequences from inaction, call for health care providers to be more proactive in the managem…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAFLD, and in particular NASH, is also associated with an increased risk of cardiovascular complications; therefore, people with NAFLD should have their cardiovascular risk factors assessed and managed to minimize this risk (303).”
In the citing paper
“Rat studies have shown that removal of visceral adipose tissue increases insulin sensitivity while delaying T2D (75), and prevents metabolic syndrome and NAFLD (76).”
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Research works printed but not linked: 1
- Sanyal, 2016, Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: results from the Year 1 primary analysis of the Phase 2b CENTAUR study (Abstract), Hepatology, 64, 1118A
Cited by
Items 201–300 of 341
Shetty, S., Suvarna, R., Fistus, V. A., Modi, S., & Pappachan, J. M. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i5.105706 · Cited by 11
Luo, H., Zhao, M., Feng, X., Gao, X., Hong, M., Liu, M., Li, Y., Liu, W., Liu, Y., Yu, C., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13469 · Cited by 11
Lee, C., Seto, W., Ieong, K., Lui, D. T. W., Fong, C. H.-Y., Wan, H. Y., Chow, W.-S., Woo, Y. C., Yuen, M., & Lam, K. S. L. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.887 · Cited by 12
Chung, G. E., Jeong, S., Cho, E. J., Yoon, J. W., Yoo, J., Cho, Y., Lee, K., Shin, D. W., Kim, Y. J., Yoon, J., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01691-6 · Cited by 13
Smad3 Mediates Diabetic Dyslipidemia and Fatty Liver in db/db Mice by Targeting PPARδ
He, H., Zhong, Y., Wang, H., Tang, P. M., Xue, V. W., Chen, X., Chen, J., Huang, X., Wang, C., & Lan, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411396 · Cited by 14
Yang, Y., Li, S., Xu, Y., Ke, J., & Zhao, D. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s350579 · Cited by 9
Peng, S., Liu, L., Xie, Z., Zhang, X., Xie, C., Ye, S., Zhang, X., Liang, X., Wang, H., & Liu, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863839 · Cited by 11
Zahoor, F., Saeed, N.-U.-S., Javed, S., Sadiq, H. Z., Khan, F. M., Haider, M., Shafqat, M. N., Maqbool, A., & Chaudhry, A. (2023) · Cureus · doi:10.7759/cureus.47240 · Cited by 9
Kytikovа, O. Y., Novgorodtseva, T. P., Denisenko, Y., & Kovalevskiy, D. A. (2020) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2020-30-2-15-25 · Cited by 10
A comprehensive approach to type 2 diabetes mellitus – A recommendation document
Reyes‐García, R., Moreno-Pérez, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Martín, J. E.-S., et al. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.10.013 · Cited by 20
Brancato, V., Pepa, G. D., Bozzetto, L., Vitale, M., Annuzzi, G., Basso, L., Cavaliere, C., Salvatore, M., Rivellese, A. A., & Monti, S. (2022) · Diagnostics · doi:10.3390/diagnostics12020514 · Cited by 10
Jeong, Y., Lee, B. J., Hur, W., Lee, M. J., & Han, S. (2024) · Metabolites · doi:10.3390/metabo14070371 · Cited by 9
Albert, S. G., & Wood, E. M. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102232 · Cited by 9
Ren, Z., Okyere, S. K., Xie, L., Wen, J., Wang, J., Chen, Z., Ni, X., Deng, J., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837237 · Cited by 10
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease
Adrian, T., Hornum, M., Knop, F. K., Almdal, T., Rossing, P. R., Lída, L. Í., Heinrich, N. S., Boer, V. O., Marsman, A., Petersen, E. T., et al. (2023) · The Nephron journals/Nephron journals · doi:10.1159/000528080 · Cited by 9
Lutz, S. Z., Hennige, A. M., Peter, A., Kovářová, M., Totsikas, C., Machann, J., Kröber, S. M., Sperl, B., Schleicher, E. D., Schick, F., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01573 · Cited by 8
Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change
Bril, F. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.11.11 · Cited by 8
Self-citationXiao, Y., Zhao, Z., Chen, B., Sun, J., Wang, L., Wang, Y., Nan, Z., & Zhang, Q. (2025) · PeerJ · doi:10.7717/peerj.19221 · Cited by 8
Mortality disparities: A comparison with the Haudenosaunee in New York State.
Haring, R. C., Jim, M. A., Erwin, D. O., Kaur, J. S., Henry, W. A. E., Haring, M., & Seneca, D. S. (2018) · PubMed · doi:10.9777/chd.2018.10009 · Cited by 8
Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
Perdomo, C. M., Núñez-Córdoba, J. M., Ezponda, A., Mendoza, F. J., Ampuero, J., Bastarrika, G., Frühbeck, G., & Escalada, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1023583 · Cited by 7
Vitale, M., Pepa, G. D., Costabile, G., Bozzetto, L., Cipriano, P., Signorini, S. G., Leoni, V., Riccardi, G., Vaccaro, O., & Masulli, M. (2022) · Nutrients · doi:10.3390/nu14245339 · Cited by 7
Fernando, J. N., Lim-Alba, R., & Alba, W. S. (2019) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.034.02.03 · Cited by 13
Maiuolo, J., Mollace, R., Bosco, F., Scarano, F., Oppedisano, F., Nucera, S., Ruga, S., Guarnieri, L., Macrì, R., Bava, I., et al. (2023) · Agriculture · doi:10.3390/agriculture13020249 · Cited by 9
Rezapour, S., Khosroshahi, S. A., Farajnia, H., Mohseni, F., Khoshbaten, M., & Farajnia, S. (2021) · BMC Research Notes · doi:10.1186/s13104-021-05586-9 · Cited by 9
Editorial: diabetes, obesity and clinical inertia—the recipe for advanced NASH
Leey, J., & Cusi, K. J. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14473 · Cited by 7
Self-citationKim, J., Han, K., Kim, B., Baek, K., Song, K., Kim, M. K., & Kwon, H. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110187 · Cited by 7
Chen, X., Xu, C., Hu, K., Yang, Y., Zhang, Y.-J., Shi, H.-Z., Gu, Q., He, S., Zhang, C., & Wang, D. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2256224 · Cited by 6
A Systematic Review of Gastrointestinal Manifestations in Diabetic Nephropathy
Zheng, S., & Ma, J. (2019) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2019.00014 · Cited by 6
Park, S. H., Lee, J., Jun, D. W., Kang, K. A., Kim, J. N., Park, H. J., & Hong, H. (2021) · Diagnostics · doi:10.3390/diagnostics11091605 · Cited by 6
Mapfumo, M., Lembede, B. W., Nkomozepi, P., Ndhlala, A. R., & Chivandi, E. (2019) · South African Journal of Botany · doi:10.1016/j.sajb.2019.05.026 · Cited by 8
Diabetes and Toxicant Exposure.
Patrick, L. (2020) · Europe PMC (PubMed Central) · Cited by 6
Meritsi, A., Latsou, D., Manesis, E. K., Gatos, I., Theotokas, I., Zoumpoulis, P. S., Rapti, S., Tsitsopoulos, E., Moshoyianni, H., Manolakopoulos, S., et al. (2022) · Clinical Diabetes · doi:10.2337/cd21-0104 · Cited by 6
Torre, E., Matteo, S. D., Bruno, G. M., Martinotti, C., Valentino, M. C., Testino, G., Rebora, A., Bottaro, L. C., & Colombo, G. L. (2022) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s371778 · Cited by 5
Xi, W., Liao, W., Li, J., Yang, Y., Guo, T., Jiang, Q., & Yang, A. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.10.018 · Cited by 5
Basic Concepts in Insulin Resistance and Diabetes Treatment
Bril, F., & Cusi, K. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-72475-1_3 · Cited by 5
Self-citationWoodard, J. S., & Abrams, G. A. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem935 · Cited by 4
Han, J., Fan, H., Dai, Y., & Cheng, X. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0105 · Cited by 4
Liu, Q., Huang, J. M., Hu, J., Ding, Y., Wang, Y., Zhang, P., Zhang, Z., Liu, Y., Li, B., Xiao, B., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70185 · Cited by 5
Pagès, M. A. I., Tavares, R., Azul, A. M., & Ramalho‐Santos, J. (2023) · Health Communication · doi:10.1080/10410236.2023.2215908 · Cited by 5
Diagnosis of Nonalcoholic Steatohepatitis
Reyes, E. C., Ojeda-Yuren, A. S., Torres‐Vázquez, J., Maceda, M. D. R. H., Vázquez‐Medina, M. U., Flores-Rangel, P. D., Velásquez-Palacios, Y. F., Cerda-Reyes, S., & Castro‐Narro, G. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96281 · Cited by 4
Faria, L. C., Diniz, M. D. F. H. S., Giatti, L., Schmidt, M. I., Goulart, A. C., Duncan, B. B., & Barreto, S. M. (2023) · Cadernos de Saúde Pública · doi:10.1590/0102-311xen090522 · Cited by 10
Cho, S. H., Kim, G., Lee, K., Oh, R., Kim, J. Y., Jang, M., Lee, Y., Jin, S., Hur, K. Y., Han, K., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0641 · Cited by 5
Lee, S., Bae, J., Kim, S. U., Lee, M., Lee, Y., Kang, E. S., Soo, B., & Lee, B. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1306134 · Cited by 3
Roh, E., Jung, H. N., Heo, J. H., Han, K., Kang, J. G., Lee, S. J., & Ihm, S. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-002020 · Cited by 3
Liman, U. U., Hawage, A. S., Silva, S. D., Samarasinghe, S. M., Tennekoon, K. H., Siriwardana, R. C., & Niriella, M. A. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00738-z · Cited by 3
Prabhakar, P., Marakala, V., Sacheendran, D., George, T., D’souza, R. K., Palatty, P. L., & Baliga, M. S. (2023) · Current Nutrition & Food Science · doi:10.2174/1573401319666230913122317 · Cited by 3
Population attributable fractions of fatty liver disease for type 2 diabetes Mellitus
Xu, J., Wu, L., Deng, J., Yang, L., Wang, Y., Tian, H., Ji, Y., Xia, Q., Han, Z., Cheng, Y., et al. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01433-z · Cited by 3
Forte, G., Donghia, R., Signorile, M. L., Tatoli, R., Bonfiglio, C., Losito, F., Marco, K. D., Manghisi, A., Guglielmi, F. A., Disciglio, V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179512 · Cited by 3
Non-Alcoholic Fatty Liver Disease
Rao, T. R., Pratiksha, B., Navyasri, C., Kalita, D. J., & Alam, S. (2023) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v13i10.6226 · Cited by 3
Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus
Liu, S., Su, K., Zhang, L., Liu, M., & Zhao, W.-X. (2020) · Medicine · doi:10.1097/md.0000000000021568 · Cited by 3
Non‐alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control
Bloomgarden, Z. T. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12566 · Cited by 3
Grigorescu, E.-D., Floria, M., Lăcătușu, C.-M., Mihai, B. M., Crețu, I., Popa, A. D., Onofriescu, A., Jaba, I. M., Șorodoc, V., Ceasovschih, A., et al. (2019) · Internal Medicine · doi:10.2478/inmed-2019-0073 · Cited by 3
Yang, D., Shen, Y., & Shuai, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331484 · Cited by 2
Mercurio, G., Giacco, A., Troise, A. D., Ledbetter, M., Pascale, S. D., Scopigno, N., Vigliotti, M., Mazzola, M., Riccio, G., Scaloni, A., et al. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70210 · Cited by 3
Wood, E. M., Akande, R. O., Iqbal, I., & Albert, S. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70314 · Cited by 2
Khosravi, Z., Barzinpour, F., Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0339580 · Cited by 2
Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes
Bril, F., Huynh, K., & Bolla, P. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0762 · Cited by 3
Self-citationMahoon, D. A., Kellany, F., Khan, I., Khan, S., & Butler, A. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125618 · Cited by 4
Sonographic Features of the Liver Among Females With Type 2 Diabetes
Riestra‐Candelaria, B. L., Gonzalez-Rodriguez, L. A., Rodríguez-Mojica, W., Vázquez-Quiñones, L. E., & Jorge, J. C. (2019) · Journal of diagnostic medical sonography · doi:10.1177/8756479319834927 · Cited by 4
Crabtree, T. S. J., Rowles, S. V., Tarpey, S., Kennedy, A., Chalmers, J., Nayar, R., Lee, A. J., Darzy, K. H., Winocour, P. H., Lindsay, J., et al. (2019) · British Journal of Diabetes · doi:10.15277/bjd.2019.227 · Cited by 2
Demidova, T. Y., Скуридина, Д. В., & Pervushina, E. S. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-17 · Cited by 2
Navarro‐Masip, È., Petit, N. M., Salinas‐Roca, B., Herrerías, F., Vilardell, F., de la Fuente, M. C., Pallarés, J., Santamaría, M., Zorzano-Martínez, M., Sánchez, E., et al. (2024) · Obesity Facts · doi:10.1159/000538765 · Cited by 5
Yue, Q., Wang, X., Liu, Y., Cai, M., Guo, S., Zhao, L., Su, L., Zhang, S., Li, B., Zhao, C., et al. (2025) · Journal of Food Biochemistry · doi:10.1155/jfbc/1706266 · Cited by 2
Alsarkhi, L. N., Eda, S., Abdul, R. H. M., Hussaini, H., Fadeyi, O. A., Chaudhari, S. S., Rauf, M. A., & Allahwala, D. (2025) · Cureus · doi:10.7759/cureus.90205 · Cited by 5
Ernährungstherapie der nichtalkoholischen Fettleber
Worm, N. (2018) · Ernährung & Medizin · doi:10.1055/a-0636-1743 · Cited by 2
YADAV, Y. R., Syn, W., & Basu, R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0158 · Cited by 2
Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia
Lee, W. D., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Han, K., & Kim, S. U. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001665 · Cited by 2
Gupta, R. V., Bhat, S. P. S., Gangadhar, P. R., Kulamarva, G., Kellari, A., & Prakash, P. (2021) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2021/64 · Cited by 2
Meritsi, A., Manesis, E. K., Koussis, P., Rapti, S., Latsou, D., Tsitsopoulos, E., Moshoyianni, H., Manolakopoulos, S., Pektasides, D., & Thanopoulou, A. C. (2021) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2021.0098 · Cited by 2
Bril, F., & Cusi, K. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00970 · Cited by 2
Self-citationKhukhlina, O. S., Hryniuk, O. Y., Антонів, А. А., & Kaushanska, O. V. (2020) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.16.6.2020.215388 · Cited by 1
Park, J.-S., Akbar, H., Kim, Y. S., & Yim, J. (2024) · Journal of Nutrition and Health · doi:10.4163/jnh.2024.57.3.282 · Cited by 1
Khatri, B., Methil, G., Bhakuni, H., & Sahu, A. K. (2024) · Journal of Ayurveda and Integrated Medical Sciences · doi:10.21760/jaims.9.6.52 · Cited by 1
Therapeutic Effects of Functional Food on Hepatic Disorders
Adhikary, K., Banerjee, A., Sadhu, D., Sarkar, R., Mohanty, S., & Karak, P. (2025) · Springer eBooks · doi:10.1007/978-981-97-9936-7_21-1 · Cited by 1
Zhang, Y., Zuo, Y., Chen, Q., Cui, Y., Bao, Y., Jiang, P., Liu, J., Quan, J., & Liu, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1724108 · Cited by 1
Deng, J., Liao, C., Liu, H., Tang, X., Yang, Y., Yang, Y., Guo, X., Zhang, S. H., Xing, K., Liao, M., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s568066 · Cited by 1
Li, C., Zhang, M., Li, M., & Shao, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1720601 · Cited by 3
Metabolomics-guided Mechanisms of Mesenchymal Stromal Cell and Exosome Therapies in Chronic Diseases
Mahmod, A. I., Govindaraju, K., Lokanathan, Y., Akmarina, N., Said, B. M., & Ibrahim, B. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11085-w · Cited by 1
Sleep habits and non‐alcoholic fatty liver disease: R isk assessment by adjusting confounders
Kawada, T. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12619 · Cited by 1
NAFLD and type 2 diabetes: A practical guide for the joint management
Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.12.010 · Cited by 1
Methods and validation of velacur determined fat fraction in patients with MASLD
Honarvar, M., Lobo, J., Schneider, C., Klein, S., Smith, G. I., Loomba, R. S., Ramji, A. S., Hassanein, T., Yoshida, E. M., Pang, E., et al. (2024) · WFUMB Ultrasound Open · doi:10.1016/j.wfumbo.2024.100061 · Cited by 1
Chen, H.-F., Chang, Y.-Y., Chen, P., Shen, X.-H., Chang, C.-H., & Hsu, W. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.104576 · Cited by 1
Glycogénose hépatique : une complication rare du diabète déséquilibré (à propos d’un cas)
Trifi, A., Abdellatif, S., Ismail, K. B., Touil, Y., Daly, F., Nasri, R., & Lakhal, S. B. (2017) · Médecine Intensive Réanimation · doi:10.1007/s13546-017-1280-1 · Cited by 2
Pavlovskyi, S. A., & Virstyuk, N. G. (2018) · World of Medicine and Biology · doi:10.26724/2079-8334-2018-1-63-61-64 · Cited by 1
Crabtree, T. S. J., YADAGIRI, M., GALLEN, I. W., Phillips, S. M., Evans, A. J., Rohilla, A., Bickerton, A. S. T., Rowles, S. V., IDRIS, I. R., Ryder, R. E. J., et al. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.239 · Cited by 1
Lee, C., Lui, D. T. W., & Lam, K. S. L. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13391 · Cited by 1
FREE FATTY ACIDS AND HEPATIC ACTIVITY IN TYPE 2 DIABETES
Mandal, Š. (2020) · RAD Conference Proceedings. · doi:10.21175/radproc.2020.19 · Cited by 1
Effects of dapagliflozin in type 2 diabetes patients with fatty liver
(2019) · Japan Journal of Medicine · doi:10.31488/jjm.1000133 · Cited by 1
Mechanistic Research into the Effects of the Jianpi Xiaozhi Formula on Liver Injury in Diabetic Rats
Zhang, Y., & Liu, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7490747 · Cited by 2
Enfermedad por esteatohepatitis no alcohólica en pacientes diabéticos tipo 2: artículo de revisión
Miranda, G. (2023) · Horizonte Médico (Lima) · doi:10.24265/horizmed.2023.v23n2.13 · Cited by 2
Obesity-mediated insulin resistance in target tissues: role of adiponectin, fetuin-A, and irisin
Mukherjee, S., Das, S., Chattopadhyay, D., & Mukhopadhyay, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00041-4 · Cited by 3
Diabetes and Non‐alcoholic Fatty Liver Disease
Mantovani, A., Targher, G., & Byrne, C. D. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch57 · Cited by 1
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
Self-citationBazhenova, N. (2018) · ScienceRise Medical Science · doi:10.15587/2519-4798.2018.147805
TRATAMIENTO DE LA ENFERMEDAD HEPÁTICA GRASA NO ALCOHÓLICA
Gutt, S., Álvarez, M., Yuma, M., Ackermann, M. A., Coronel, M., Gauna, C., González, S., Lifszyc, P., Menéndez, E., Mociulsky, J., et al. (2018) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v52i1.80 · Cited by 1
Fülöp, G. Á., Dezső, L., & Wittmann, I. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.4
Ferreira, M. M. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.100.2020.tde-19122019-134105
Manejo de la enfermedad hepática metabólica grasa
Lucena, A., Torrijo, Y. S., & Herrojo, J. A. (2020) · Revista Andaluza de Patología Digestiva · doi:10.37352/2020432.2
Advanced Liver Fibrosis in Peruvian Patients with Type 2 Diabetes Mellitus: A cross-sectional Study
Lozano, A. (2020) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2020.15.555903
Escalada, J. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.7148/2020
Metadata
- Authors
- Bril, F., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Cusi, Kenneth
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-02-13
- Volume
- 40
- Issue
- 3
- Pages
- 419-430
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2589426226
- Cited by
- 341
- References
- 123
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 28 · 2023: 38 · 2022: 41 · 2021: 43 · 2020: 61 · 2019: 41 · 2018: 36 · 2017: 17
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, nonalcoholic steatohepatitis, metabolic syndrome, obesity, liver cirrhosis, hepatocellular carcinoma, NASH diagnosis, NASH treatment, disease natural history
- MeSH terms
- Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Humans, Hyperglycemia, Life Style, Liver Neoplasms, Obesity, Risk Factors, Prevalence, Randomized Controlled Trials as Topic, Metabolic Syndrome, Dyslipidemias, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.